1. Home
  2. ENLT vs BLCO Comparison

ENLT vs BLCO Comparison

Compare ENLT & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enlight Renewable Energy Ltd.

ENLT

Enlight Renewable Energy Ltd.

HOLD

Current Price

$45.40

Market Cap

5.4B

Sector

N/A

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$17.06

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENLT
BLCO
Founded
2008
1853
Country
Israel
Canada
Employees
N/A
N/A
Industry
Ophthalmic Goods
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.0B
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
ENLT
BLCO
Price
$45.40
$17.06
Analyst Decision
Buy
Hold
Analyst Count
6
14
Target Price
$37.50
$17.31
AVG Volume (30 Days)
32.1K
325.5K
Earning Date
02-18-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
132.72
N/A
EPS
0.96
N/A
Revenue
$457,756,000.00
$4,976,000,000.00
Revenue This Year
$355.90
$8.06
Revenue Next Year
$42.83
$5.79
P/E Ratio
$48.77
N/A
Revenue Growth
27.72
6.23
52 Week Low
$14.01
$10.45
52 Week High
$45.82
$18.55

Technical Indicators

Market Signals
Indicator
ENLT
BLCO
Relative Strength Index (RSI) 66.61 58.31
Support Level $41.66 $16.94
Resistance Level $45.73 $17.23
Average True Range (ATR) 1.29 0.30
MACD 0.27 -0.04
Stochastic Oscillator 92.91 45.11

Price Performance

Historical Comparison
ENLT
BLCO

About ENLT Enlight Renewable Energy Ltd.

Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: